<\/p>\n
Most 140-year-old companies are coasting. Johnson & Johnson (JNJ) is restructuring. And that’s the part of the J&J story that rarely gets enough attention.\u00a0<\/p>\n
When people think of this company, they think of dividend checks and baby powder. A steady, predictable blue-chip that you hold forever and never think about. That image is accurate in some ways, but it misses what’s actually happening beneath it.<\/p>\n
J&J is actively separating its orthopaedics division, doubling down on oncology, and preparing for a Dec. 8 Enterprise Business Review that could reframe the entire investment thesis for years ahead.\u00a0<\/p>\n
CEO Joaquin Duato just guided the company toward more than $100 billion in annual revenue for the first time in its 140-year history, according to its Q2 2026 results. And the dividend? It just hit 64 consecutive years of increases without missing a beat.<\/p>\n
This is not only a legacy company standing still. It’s a legacy company deliberately reshaping itself. And Dec. 8 is when we find out exactly what that reshaping looks like.<\/p>\n
Also Read: Johnson & Johnson Latest News and Stories<\/p>\n
Why J&J is separating its orthopaedics business<\/p>\n
In October 2025, Johnson & Johnson shared plans to spin off its orthopaedics division into a stand-alone publicly traded company called DePuy Synthes. The separation is targeted for completion within 18 to 24 months from that announcement date, subject to board approval and regulatory clearances.<\/p>\n
DePuy Synthes isn’t a weak business being discarded. In fact, it’s the world’s largest orthopaedics-focused company, serving a global market worth more than $50 billion and generating approximately $9.2 billion in sales in 2024, according to Johnson & Johnson. Namal Nawana has been appointed to lead it as a stand-alone entity.<\/p>\n
More Healthcare\/Health:<\/p>\n
One IRA withdrawal can triple your Medicare premiumUnitedHealth\u2019s earnings comeback hides a risk Wall Street can\u2019t priceMedicare\u2019s new $50 GLP-1 deal has a catch<\/p>\n
So why separate a $9 billion business that’s working? Because J&J is playing a different game now.\u00a0<\/p>\n
The company wants capital, management attention, and investor perception aligned around six faster-growing areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.\u00a0<\/p>\n
Orthopaedics, while valuable, grows at a different pace than what J&J is building toward. Spinning it out sharpens focus and may unlock value on both sides of the split.<\/p>\n
Related: Johnson & Johnson bets $1 billion on hard-to-treat cancer<\/p>\n
My understanding is that this is the same playbook J&J used when it spun off Kenvue, the consumer health business, in 2023. Yes, it works.\u00a0<\/p>\n
The remaining entity trades at a higher multiple because the growth profile improves. DePuy Synthes becomes a focused pure-play that institutional investors can size appropriately. Everyone wins.<\/p>\n
Oncology is J&J\u2019s growth engine, and the numbers back it up<\/p>\n
If orthopaedics is what J&J is walking away from, oncology is where it’s running toward.<\/p>\n
The company is targeting $50 billion in annual oncology drug sales by 2030, according to a Barron\u2019s report. That’s a pretty ambitious number. And the Q2 2026 results actually suggest the trajectory is real.<\/p>\n
Innovative Medicine, J&J’s pharmaceutical segment, reported sales of $16.38 billion in Q2 fiscal 2026, up 7.8% year over year (YoY), according to a J&J statement.<\/p>\n
The key drivers were DARZALEX, CARVYKTI, TECVAYLI, and RYBREVANT in oncology, besides TREMFYA in immunology.\u00a0<\/p>\n
STELARA declines \u2014 expected as biosimilar competition increases \u2014 were more than offset by growth across the newer portfolio.<\/p>\n
Total company reported sales surpassed $25.3 billion in Q2, up 6.6% YoYAdjusted diluted earnings per share (EPS) came in at $2.90, up 4.7% YoYFree cash flow reached approximately $8.7 billion year-to-date
\nSource: Johnson & Johnson Q2 2026 Results<\/p>\n
J&J raised its full-year 2026 guidance following the quarter. The company now expects reported sales of $100.8 billion to $101.4 billion and adjusted diluted EPS of $11.60 to $11.75, up from prior guidance in both cases.<\/p>\n
Duato framed the milestone, stating: “Quarterly sales surpassing $25 billion \u2014 we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company’s 140-year history.”<\/p>\n
CEO Joaquin Duato just guided Johnson & Johnson toward more than $100 billion in annual revenue for the first time in its 140-year history.<\/p>\n
Heather Diehl/Getty Images<\/p>\n
The talc settlement that cleared a major J&J overhang<\/p>\n
Even before looking ahead to December, it\u2019s worth acknowledging what J&J has put behind it. The company offered up to $5.5 billion to settle talc-related lawsuits involving its baby powder, covering approximately 76,000 cases, according to BBC reporting.\u00a0<\/p>\n
J&J has denied that its talc products caused cancer and changed the formula of its baby powder.<\/p>\n
Also Read: History of Johnson & Johnson: Timeline and Facts<\/p>\n
The settlement provides clearer visibility on future cash demands. That means a meaningful unlock for investors who had been discounting the stock for legal uncertainty.<\/p>\n
The proposal requires acceptance by legal firms representing 95% of ovarian cancer claims in state and federal courts before it can be finalized.<\/p>\n
Here is why Dec. 8 is the date every J&J investor should mark<\/p>\n
J&J’s Enterprise Business Review is scheduled for Dec. 8, 2026. This is where management is expected to deliver a detailed deep dive on long-term growth targets, pipeline execution, and capital allocation as the company tracks toward its goal of double-digit growth by the end of the decade.<\/p>\n
The orthopaedics separation timeline, the oncology buildout toward $50 billion, and the post-settlement capital picture all converge at that event. It’s the moment J&J management will either prove the restructuring thesis convincingly or leave investors wanting more.<\/p>\n
JNJ shares were trading at $259.24, up 26.66% year to date and 54.91% over the past year, according to Yahoo Finance at the time of this reporting. The S&P 500 returned 13.32% and 22.36% over those same periods. J&J also declared a third-quarter 2026 dividend of $1.34 per share, payable Sept. 8, 2026.<\/p>\n
Sixty-four years of dividend growth. A $100 billion revenue milestone. A strategic separation designed to unlock faster growth. Dec. 8 is when J&J makes the full case for what comes next.<\/p>\n
Related: J&J\u2019s biotech progress could punish its 2027 profit<\/p>\n
#140yearold #Dividend #King #eyes #bold #update #unlock #growth<\/p>\n","protected":false},"excerpt":{"rendered":"
Most 140-year-old companies are coasting. Johnson & Johnson (JNJ) is restructuring. And that’s the part…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[17919,2602,186,908,1737,431,4083,4013],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/13275"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13275"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/13275\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}